GlassScriptPhysician profile
Matthew L Carr
NPI 1447252135
$51,383.69
in general payments reported to CMS, 2019-2025
44 companies · $916 in 2025
The $916 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $91.45 · 2021: $24K · 2022: $12K · 2023: $10K · 2024: $4,381 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,450 · Consulting Fee: $5,163 · Food and Beverage: $3,285 · Travel and Lodging: $350 · Education: $71.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,450.00 |
| Consulting Fee | $5,162.50 |
| Food and Beverage | $3,284.72 |
| Travel and Lodging | $350.00 |
| Education | $71.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $25,827.00 | 2021-2023 | |
| Daiichi Sankyo INC. | $9,740.68 | 2021-2024 | Vanflyta |
| Astellas Pharma US INC | $9,620.21 | 2021 | |
| Seagen INC. | $1,750.00 | 2023 | |
| Karyopharm Therapeutics INC. | $356.78 | 2021-2024 | Xpovio |
| Myriad Genetic Laboratories, INC. | $355.65 | 2023-2025 | Myrisk |
| Janssen Biotech, INC. | $350.00 | 2019-2025 | Erleada, Akeega, Tecvayli |
| Intuitive Surgical, INC. | $243.99 | 2019-2024 | |
| Amgen INC. | $241.57 | 2019-2023 | Lumakras, Kyprolis |
| Eisai INC. | $234.76 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $232.12 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $223.66 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $213.77 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Kite Pharma, INC. | $175.47 | 2021-2025 | Yescarta |
| Abbvie INC. | $153.95 | 2024-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$180,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.